心速宁多靶点作用机制的网络药理学研究
心速宁是2005年起用于治疗室性早搏的中成药,由11味中药组成,适用于痰热扰心证心律失常。本研究引入新系数模拟组方中各组分的相对含量,结合细胞电生理数据构建其药理机制全景图。通路富集分析显示心速宁通过多离子通道调控、抗心肌缺血再灌注损伤、抑制心肌细胞凋亡及改善糖脂代谢治疗痰热扰心证心律失常。
要点
- 心速宁由11味中药组成,适用于痰热扰心证室性早搏。
- 新系数可反映组方中各组分相对含量并用于通路加权。
- 心速宁经多离子通道调控等多通路发挥抗心律失常作用。
核心结论
- 心速宁通过多离子通道调控、保护心脏免受缺血再灌注损伤、抑制心肌细胞凋亡及改善糖脂代谢治疗痰热扰心证心律失常。
研究设计与样本
- 本研究为网络药理学/系统药理学研究,引入新系数模拟心速宁组方11味中药中各组分相对含量,并结合实验室细胞电生理数据。
主要发现
- 通路富集与分析显示心速宁通过多离子通道调控、保护心脏免受缺血再灌注损伤、抑制心肌细胞凋亡及改善糖脂代谢治疗痰热扰心证心律失常。
- 莲心碱和异甘草素对NaV1.5通道的作用被设为该两成分的靶点之一,支持心速宁治疗快速性心律失常的临床疗效。
临床怎么用
- 本研究提示心速宁适用于痰热扰心证心律失常,其作用涉及多离子通道、缺血再灌注损伤、凋亡及糖脂代谢等多条通路。
局限性
- 网络药理学/系统药理学通常对所有组分同等加权,忽略组分重量占比,本研究虽引入新系数但原文未报告其验证情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Xin Su Ning (XSN) is a China patented and certified traditional Chinese herbal medicine used to treat premature ventricular contractions (PVCs) since 2005. XSN is formulated with 11 herbs, designed to treat arrhythmia with phlegm-heat heart-disturbed syndrome (PHHD) according to Chinese medicine theory. The rational compatibility of the 11 herbs decides the therapeutic outcome of XSN. Due to the multicomponent nature of traditional Chinese medicine, it is difficult to use conventional pharmacology to interpret the therapeutic mechanism of XSN in terms of clear-cut drug molecule and target interactions. Network pharmacology/systematic pharmacology usually consider all the components in a formula with the same weight; therefore, the proportion of the weight of the components has been ignored. In the present study, we introduced a novel coefficient to mimic the relative amount of all the components in relation with the weight of the corresponding herb in the formula. The coefficient is also used to weigh the pharmacological effect of XSN on all relative biological pathways. We also used the cellular electrophysiological data generated in our lab, such as the effect of liensinine and isoliquiritigenin on NaV1.5 channels; we therefore set sodium channel as one of the targets of these two components, which would support the clinical efficacy of XSN in treating tachyarrhythmia. Combining the collected data and our discovery, a panoramagram of the pharmacological mechanism of XSN was established. Pathway enrichment and analysis showed that XSN treated PHHD arrhythmia through multiple ion channels regulation, protecting the heart from I/R injury, inhibiting the apoptosis of cardiomyocyte, and improving glucose and lipid metabolism.
引用
- Wang T, Streeter H, Wang X, et al. A Network Pharmacology Study of the Multi-Targeting Profile of an Antiarrhythmic Chinese Medicine Xin Su Ning. Front Pharmacol. 2019. PMID: 31607935. doi:10.3389/fphar.2019.01138
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。